D. Volz

Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with non‐transfusion‐dependent β‐thalassaemia

J. Dukart, M. Cappellini, C. Brugnara, 2021, British journal of haematology.

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.

D. Grobbee, L. Rydén, J. Tardif, 2014, JAMA.

Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes.

R. Califf, L. Ruilope, H. Gerstein, 2015, American heart journal.

GANTENERUMAB TREATMENT REDUCES BIOMARKERS OF NEURONAL AND SYNAPTIC DEGENERATION IN ALZHEIMER’S DISEASE

K. Blennow, P. Scheltens, J. Dukart, 2016, Alzheimer's & Dementia.

Noninvasive glucose measurement by monitoring of scattering coefficient during oral glucose tolerance tests. Non-Invasive Task Force.

L Heinemann, D Volz, T Heise, 2000, Diabetes technology & therapeutics.

Efficacy, Safety and Biomarker Data from SCarlet RoAD - A Global Phase 3 Study of Gantenerumab in Patients with Prodromal AD (S1.002)

P. Scheltens, B. Dubois, M. Boada, 2016 .

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.

D. Grobbee, L. Rydén, J. Tardif, 2014, JAMA.